Details

Autor(en) / Beteiligte

• Chopra, H K
• Wander, G S
• Nair, Tiny
• Ponde, C K
• Nanda, Navin C
• Narula, Jagat
• Ray, Saumitra
• Venugopal, K
• Iyengar, S S
• Kasliwal, R R
• Chandra, Praveen
• Prakash, Sunil
• Bansal, Sandeep
• Rana, D S
• Kerkar, Prafulla
• Dasbiswas, Arup
• Sawhney, Jps
• Shanmungasundram, S
• Kumar, Viveka
• Vijayalakshmi, I B
• Pancholia, A K
• Sharma, Vinod
• Kapoor, Aditya
• Swami, Onkar C
• Isser, H S
• Rastogi, Vishal
• Arora, Y K
• Omar, Ashok K
• Sathe, Sunil
• Rajput, Rajeeve
• Prabhakar, D
• Paul, G J
• Jagia, Priya
• Malhotra, Poonam
• Suryaprakash, G
• Mittal, Vinod
• Jagia, Manish
• Jabir, A
• Mishra, S S
• Routray, S N
• Sinha, Ajay K
• Bhargava, Mohan
• Mahmood, Kiran
• Bhatia, Mona
• Kalra, Pramila
• Katyal, V K
• Tandon, Rohit
• Grover, Rahul
• Chhabra, Abhinav
• Shastry, N R

Titel

Role of Iron Therapy in Heart Failure: A Consensus Statement from India

Ist Teil von

• Journal of the Association of Physicians of India, 2023-03, Vol.71 (3), p.11-87

Ort / Verlag

India

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Iron deficiency (ID) with or without anemia is frequently observed in patients with heart failure (HF). Uncorrected ID is associated with higher hospitalization and mortality in patients with acute HF (AHF) and chronic HF (CHF). Hence, in addition to chronic renal insufficiency, anemia, and diabetes, ID appears as a novel comorbidity and a treatment target of CHF. Intravenous (IV) ferric carboxymaltose (FCM) reduces the hospitalization risk due to HF worsening and improves functional capacity and quality of life (QOL) in HF patients. The current consensus document provides criteria, an expert opinion on the diagnosis of ID in HF, patient profiles for IV FCM, and correct administration and monitoring of such patients.